Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

B. E. Sands, B. D. Winston, B. Salzberg, M. Safdi, C. Barish, L. Wruble, R. Wilkins, M. Shapiro, U. S. Schwertschlag

Research output: Contribution to journalArticlepeer-review

141 Scopus citations

Abstract

Background: Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease. Aim: To determine the safety and preliminary estimate of efficacy of rhIL-11 in treating active Crohn's disease. Methods: Patients with mild to moderately active Crohn's disease, defined as a Crohn's disease activity index (CDAI) ≥ 220 and ≤ 450, were enrolled in a multicentre trial. Stable doses of 5-aminosalicylates, antibiotics, 6-mercaptopurine or azathioprine were permitted with appropriate wash-in periods. Oral, intravenous or rectally administered corticosteroids were not allowed. Patients were randomized to 6 weeks of subcutaneous injection with rhIL-11 15 μg/kg or placebo weekly, or rhIL-11 7.5 μg/kg or placebo twice weekly. The primary end-point was per cent change in CDAI at week 6; the major secondary end-point was the proportion of patients in remission, defined as a 100 point decrease in CDAI and absolute CDAI ≤ 150. Results: Baseline characteristics were similar among the 148 evaluated patients (49 placebo, 49 rhIL-11 15 μg/kg once weekly, 50 rhIL-11 7.5 μg/kg twice weekly). Treatment was well-tolerated, with mild injection site reactions occurring more frequently among patients treated with rhIL-11. Headache, oedema, and increased platelet count occurred significantly more often in the rhIL-11 7.5 μg/kg twice weekly group, but not the 15 μg/kg once weekly group. There was a trend toward decreased mean per cent change in CDAI in the rhIL-11 15 μg/kg once weekly group vs. placebo (-31.5% vs. - 18.5%, 95% confidence interval for the difference - 27.9-1.6%). A significantly greater proportion of patients receiving rhIL-11 15 μg/kg once weekly achieved remission compared to placebo (36,7% vs. 16.3%, 95% confidence interval for the difference 3.4-37.4%; 16.4% for rhIL-11 7.5 μg/kg, N.S.). Conclusions: Weekly subcutaneous injection with rhIL-11 15 μg/kg is safe and effective in inducing remission in a subset of patients with active Crohn's disease.

Original languageEnglish
Pages (from-to)399-406
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Dive into the research topics of 'Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease'. Together they form a unique fingerprint.

Cite this